Why the study?
Does the addition of carvedilol and eprosartan improve hemodynamics and exercise tolerance in patients with metabolic syndrome and chronic heart failure?
Does the addition of carvedilol and eprosartan improve hemodynamics and exercise tolerance in patients with metabolic syndrome and chronic heart failure?
The addition of carvedilol and eprosartan to standard therapy significantly improves blood pressure, heart rate, and exercise tolerance in patients with metabolic syndrome and chronic heart failure.
May support adjunctive carvedilol-eprosartan use in metabolic syndrome with heart failure; hypothesis-generating and requires randomized confirmation.
А im. of the study was to assess the effectiveness of carvedilol and eprosartan in addition to the traditional treatment (Nitrosorbid 30mg/day + Digoxin 0.25mg/day + TromboASS 100mg/day + Atorvastatin 20mg/day + Furosemid 40mg/day + Verospiron 50mg/day + Atenolol 12.5–25 mg/day) in patients with metabolic syndrome and chronic heart failure. Materials and methods . 91 patients with MS and CHF included sharing mentioned criteria. Carvedilol in doses of 6,25 ÷ 25 mg/day and eprosartan in doses of 300 ÷ 600 mg/day were administered in addition to the traditional treatment. Results . After 12 months of treatment systolic BP decreased by 23.6% and diastolic by 17.2%. Heart rate decreased by 23.1%, and exercise tolerance increased by 22.3%. Dynamics of the presented indicators are statistically significant. Conclusion . Administration of an alpha-beta blocker carvedilol and angiotensin II receptor blocker eprosartan in the above dosages promote the longest remission of heart failure, improvement in functional class and regression of pathological remodeling.
No takes yet. Share an insight, caveat, or question.
R. L. Dashnamirov (2014) studied this question.